NCT05201547: Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line
- State
- Under way
- Phase
- Phase 3
- People
- 260 planned
- Started
- 15 Apr 2022
- Primary completion
- 1 Oct 2026
- Arms
- Arm A: Dostarlimab 500 mg, every 3 weeks, 4 cycles and then 1000 mg every 6 weeks
- Results
- None posted
- 21 Jan 2022: Trial registered
- 15 Apr 2022: Trial started